In an early look at its annual earnings report, Guardant Health posted revenue gains of 31%—with the $737 million total ...

Oxford University researchers have unveiled a new blood test, powered by machine learning, that shows promise in detecting ...

They’re non-invasive with none of the dreaded prep. But are recently approved home tests for colon cancer as effective as ...

In 2024, the FDA approved at-home blood and stool tests for colorectal cancer screenings. In October, a second iteration of the at-home stool test was approved. While new, less-invasive blood tests ...

Exact Sciences' 2024 sales grew 10% to $2.76 billion, exceeding estimates. New cancer tests, including Cologuard Plus, are ...

Mirxes, a leading Singapore-based cancer detection firm, has secured $40 million in financing from CBC Group's R-Bridge Fund to enhance its innovative miRNA technology platform. The investment aims to ...

R-Bridge will provide bespoke financing of US$40 million with a synthetic royalty structure and flexible repayment terms - Financing will accelerate Mirxes, Singapore-based miRNA tech ...

Tackle cancer risk with evidence-based resolutions inspired by the Latin American and Caribbean Code Against Cancer.

More than 66,000 Americans will be diagnosed with pancreatic cancer this year. Learn more about the disease and how PanCAN can help.